{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-2.5-pro",
  "metadata": {
    "studyName": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Dise",
    "titles": [
      {
        "id": "title_1",
        "text": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
        "type": {
          "code": "Brief Study Title",
          "codeSystem": "USDM",
          "decode": "Brief Study Title"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "id_1",
        "text": "NCT04573309",
        "scopeId": "org_ct_gov",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "id_2",
        "text": "ALXN1840-WD-204",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "id_3",
        "text": "2020-001104-41",
        "scopeId": "org_unknown",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "id_4",
        "text": "119006",
        "scopeId": "org_2",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Alexion Pharmaceuticals, Inc.",
        "type": {
          "code": "Pharmaceutical Company",
          "codeSystem": "USDM",
          "decode": "Pharmaceutical Company"
        },
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "US Food and Drug Administration (FDA)",
        "type": {
          "code": "Government Institute",
          "codeSystem": "USDM",
          "decode": "Government Institute"
        },
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Regulatory Agency",
        "code": {
          "code": "Regulatory Agency",
          "codeSystem": "USDM",
          "decode": "Regulatory Agency"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "indication_1",
        "name": "Wilson Disease",
        "isRareDisease": true,
        "instanceType": "Indication",
        "description": "A study to assess copper and molybdenum balance in participants with Wilson Disease treated with ALXN1840."
      }
    ],
    "studyPhase": {
      "code": "Phase 2",
      "codeSystem": "USDM",
      "decode": "Phase 2"
    },
    "studyType": "Interventional",
    "protocolVersion": "3.1 (US)",
    "protocolDate": "2022-03-18",
    "amendmentNumber": "3.1"
  },
  "rawResponse": {
    "titles": [
      {
        "type": "Official Study Title",
        "text": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840"
      },
      {
        "type": "Brief Study Title",
        "text": "Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840"
      },
      {
        "type": "Study Acronym",
        "text": null
      },
      {
        "type": "Scientific Study Title",
        "text": null
      }
    ],
    "identifiers": [
      {
        "type": "NCT Number",
        "value": "NCT04573309",
        "registry": "ClinicalTrials.gov"
      },
      {
        "type": "Sponsor Protocol Number",
        "value": "ALXN1840-WD-204",
        "registry": "Sponsor"
      },
      {
        "type": "EudraCT Number",
        "value": "2020-001104-41",
        "registry": "European Union Drug Regulating Authorities Clinical Trials Database"
      },
      {
        "type": "IND/IDE Number",
        "value": "119006",
        "registry": "FDA"
      }
    ],
    "organizations": [
      {
        "name": "Alexion Pharmaceuticals, Inc.",
        "role": "Sponsor",
        "type": "Pharmaceutical Company"
      },
      {
        "name": "US Food and Drug Administration (FDA)",
        "role": "Regulatory Agency",
        "type": "Government"
      }
    ],
    "studyPhase": "Phase 2",
    "indication": {
      "name": "Wilson Disease",
      "description": "A study to assess copper and molybdenum balance in participants with Wilson Disease treated with ALXN1840.",
      "isRareDisease": true
    },
    "studyType": "Interventional",
    "protocolVersion": {
      "version": "3.1 (US)",
      "date": "2022-03-18",
      "amendment": "3.1"
    }
  }
}